Omadacycline for community-acquired bacterial pneumonia

New England Journal of Medicine

Volumn 380, Issue 6, 2019, Pages 517-527

  Stets, Roman ^a   Popescu, Monica ^b   Gonong, Joven R ^c   Mitha, Ismail ^d   Nseir, William ^e   Madej, Andrzej ^f   Kirsch, Courtney ^h   Das, Anita F ^g   Garrity Ryan, Lynne ^h   Steenbergen, Judith N ^h   Manley, Amy ^h   Eckburg, Paul B ^h   Tzanis, Evan ^h   McGovern, Paul C ^h   Loh, Evan ^h  

^a City Clinical Hospital 6   (Ukraine)

^b Sf Pantelimon Clin Emergency Hosp   (Romania)

^c Lung Center of the Philippines   (Philippines)

^d Lakeview Hospital   (South Africa)

^e BAR ILAN UNIVERSITY   (Israel)

^f ANDRZEJ FRYCZ MODRZEWSKI KRAKOW UNIVERSITY   (Poland)

^g AD Stats Consulting   (United States)

^h Transcept Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MOXIFLOXACIN; OMADACYCLINE; ANTIINFECTIVE AGENT; TETRACYCLINE DERIVATIVE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; COMMUNITY ACQUIRED PNEUMONIA; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; DYSPNEA; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEADACHE; HUMAN; HYPERTENSION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; PNEUMONIA SEVERITY INDEX; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SPUTUM; SURVIVAL; THORAX PAIN; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; BACTERIAL PNEUMONIA; BACTERIUM; CLINICAL TRIAL; COMMUNITY ACQUIRED INFECTION; COMPARATIVE STUDY; DRUG ADMINISTRATION; HOSPITALIZATION; INTENTION TO TREAT ANALYSIS; INTRAVENOUS DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIA; COMMUNITY-ACQUIRED INFECTIONS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HOSPITALIZATION; HUMANS; INFUSIONS, INTRAVENOUS; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED; MOXIFLOXACIN; PNEUMONIA, BACTERIAL; TETRACYCLINES;

EID: 85061126850     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1800201     Document Type: Article

References (32)

1. Violi F, Cangemi R, Falcone M, et al. Cardiovascular complications and short-term mortality risk in community-acquired pneumonia. Clin Infect Dis 2017;64:1486-93.
2. File TM Jr, Marrie TJ. Burden of community-acquired pneumonia in North American adults. Postgrad Med 2010;122: 130-41.
3. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 2012;67:71-9.
4. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013 (https://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar -threats-2013-508.pdf).
5. World Health Organization. Antimicrobial resistance: global report on surveillance. 2014 (http://www.who.int/drugresistance/documents/surveillancereport/en/).
6. World Health Organization. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. 2017 (http://apps.who.int/medicinedocs/documents/ s23171en/s23171en.pdf).
7. Honeyman L, Ismail M, Nelson ML, et al. Structure-activity relationship of the aminomethylcyclines and the discovery of omadacycline. Antimicrob Agents Chemother 2015;59:7044-53.
8. Villano S, Steenbergen J, Loh E. Omadacycline: development of a novel aminomethylcycline antibiotic for treating drug-resistant bacterial infections. Future Microbiol 2016;11:1421-34.
9. Pfaller MA, Huband MD, Rhomberg PR, Flamm RK. Surveillance of omadacycline activity against clinical isolates from a global collection (North America, Europe, Latin America, Asia-Western Pacific), 2010-2011. Antimicrob Agents Chemother 2017;61(5):e00018-17.
10. Tanaka SK, Steenbergen J, Villano S. Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic. Bioorg Med Chem 2016; 24:6409-19.
11. Lepak AJ, Zhao M, Marchillo K, Van-Hecker J, Andes DR. In vivo pharmacody-namic evaluation of omadacycline (PTK 0796) against Streptococcus pneumoniae in the murine pneumonia model. Antimicrob Agents Chemother 2017;61(5):e02368-16.
12. Gotfried MH, Horn K, Garrity-Ryan L, et al. Comparison of omadacycline and tigecycline pharmacokinetics in the plasma, epithelial lining fluid, and alveolar cells of healthy adult subjects. Antimicrob Agents Chemother 2017;61(9):e01135-17.
13. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336:243-50.
14. Farrington CP, Manning G. Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. Stat Med 1990;9:1447-54.
15. Community-acquired bacterial pneumonia: developing drugs for treatment - guidance for industry. Silver Spring, MD: FDA Center for Drug Evaluation and Research, January 2014 (https://www.fda.gov/downloads/Drugs/GuidanceCompliance RegulatoryInformation/Guidances/ UCM123686.pdf).
16. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med 1985; 4:213-26.
17. Marrie TJ, Beecroft MD, Herman-Gnjidic Z. Resolution of symptoms in patients with community-acquired pneumonia treated on an ambulatory basis. J Infect 2004;49:302-9.
18. Menéndez R, Torres A, Rodríguez de Castro F, et al. Reaching stability in community-acquired pneumonia: the effects of the severity of disease, treatment, and the characteristics of patients. Clin Infect Dis 2004;39:1783-90.
19. Metlay JP, Atlas SJ, Borowsky LH, Singer DE. Time course of symptom resolution in patients with community-acquired pneumonia. Respir Med 1998;92:1137-42.
20. Deshpande A, Pasupuleti V, Thota P, et al. Community-associated Clostridium difficile infection and antibiotics: a meta-analysis. J Antimicrob Chemother 2013; 68:1951-61.
21. Tariq R, Cho J, Kapoor S, et al. Low risk of primary Clostridiumdifficile infection with tetracyclines: a systematic review and meta-analysis. Clin Infect Dis 2018;66:514-22.
22. Hung YP, Lee JC, Lin HJ, et al. Doxycy-cline and tigecycline: two friendly drugs with a low association with ClostridiumDif-ficile infection. Antibiotics (Basel) 2015;4: 216-29.
23. File TM Jr, Low DE, Eckburg PB, et al. FOCUS 1: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother 2011;66: Suppl 3:iii19-iii32.
24. File TM Jr, Rewerska B, Vucinic-Mihailovic V, et al. SOLITAIRE-IV: a randomized, double-blind, multicenter study comparing the efficacy and safety of intravenous-to-oral solithromycin to intravenous-to-oral moxifloxacin for treatment of community-acquired bacterial pneumonia. Clin Infect Dis 2016;63:1007-16.
25. Low DE, File TM Jr, Eckburg PB, et al. FOCUS 2: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother 2011;66: Suppl 3:iii33-iii44.
26. Mortensen EM, Coley CM, Singer DE, et al. Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study. Arch Intern Med 2002;162:1059-64.
27. Yuan X, Liang BB, Wang R, et al. Treatment of community-acquired pneumonia with moxifloxacin: a meta-analysis of randomized controlled trials. J Chemother 2012;24:257-67.
28. Spellberg B, Guidos R, Gilbert D, et al. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis 2008; 46:155-64.
29. Rennie RP, Ibrahim KH. Antimicrobial resistance in Haemophilusinfluenzae: how can we prevent the inevitable? Commentary on antimicrobial resistance in H. influenzae based on data from the TARGETed surveillance program. Clin Infect Dis 2005; 41:Suppl 4:S234-S238.
30. Flamm RK, Steenbergen JN, Huband MD, Rhomberg PR, Sader HS. Activity of omadacycline when tested against respiratory pathogens Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and Staphylococcus aureus isolated during 2016 from medical centers in the USA. Am J Respir Crit Care Med 2017;195:A6856. abstract.
31. Bartlett JG. Diagnostic tests for agents of community-acquired pneumonia. Clin Infect Dis 2011;52:Suppl 4:S296-S304.
32. Jain S, Self WH, Wunderink RG, et al. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med 2015;373:415-27.